Mer­ck KGaA taps UK can­cer re­search or­ga­ni­za­tions to feed pipeline

Af­ter an R&D drought that last­ed more than a decade, Mer­ck KGaA may be com­ing out of the desert. Fol­low­ing two re­cent drug ap­provals, in­clud­ing the land­mark FDA OK for check­point in­hibitor Baven­cio, the Ger­man Mer­ck is now en­ter­ing an R&D col­lab­o­ra­tion that might help fill its pipeline with new can­cer drug con­tenders.

The com­pa­ny is team­ing up with Can­cer Re­search UK and the In­sti­tute of Can­cer Re­search, Lon­don for three re­search projects and a li­cens­ing deal. The group will be do­ing dis­cov­ery-stage work look­ing for tar­gets and pre­clin­i­cal can­di­dates.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.